Route 66 Endometrial Cancer SPORE

项目摘要 66号公路子宫内膜癌孢子汇集了来自三个机构的互动研究团队， 创建一个动态的转化研究计划，旨在开发和测试新的战略，以防止 治疗子宫内膜癌这个SPORE包括三个研究项目;一个行政核心;一个 生物统计学和生物信息学核心;生物标本，代谢组学和病理学核心;以及发展 研究和职业发展计划。这三个项目，选择和完善了广泛的投入， 我们的内部和外部咨询委员会，旨在具有改变临床实践的巨大潜力 五年内项目1：晚期和复发性子宫内膜癌治疗中的HSPA蛋白。项目二： 抑制AXL以改善子宫内膜癌的治疗反应。项目3：改善初级教育 绝经前妇女肥胖及子宫内膜增生的预防和子宫保留。 项目1和2是临床/转化项目，而项目3是早期发现、预防或治疗项目。 人口科学项目。这三个项目都包括临床试验，代表了精心挑选的婚姻 子宫内膜癌的研究重点和华盛顿大学在圣路易斯的优势。 路易斯和我们在新墨西哥州大学和俄克拉荷马州健康科学大学的合作者 中心我们的SPORE的总体目标是：1）测试有希望的新疗法来治疗或预防子宫内膜异位症。 2）阐明驱动子宫内膜癌的关键生物学过程，并开发新的生物标志物， 预测子宫内膜癌的发展和对治疗的反应; 3）利用和提高 共享研究资源; 4）招募和指导新的研究人员，并支持创新的想法， 转化子宫内膜癌研究; 5）促进对子宫内膜癌感兴趣的人的合作 研究; 6）确保临床试验的公平招募和不同社区成员的参与 和研究人员。在完成这里提出的工作时，我们将测试三种新策略， 预防或治疗子宫内膜癌。未来的工作可以针对移动最有前途的治疗 进入更大的试验。此外，我们将获得前所未有的分子，细胞， 关于子宫内膜癌和对治疗反应的免疫学和代谢组学细节， 从而导致开发更多新的临床试验。最后，通过开发新的想法，调查人员， 通过合作，我们将扩大旨在治疗或预防子宫内膜异位症的研究的广度和深度。 癌

PROJECT SUMMARY The Route 66 Endometrial Cancer SPORE brings together interactive research teams from three institutions to create a dynamic translational research program aimed at developing and testing new strategies to prevent and treat endometrial cancer. This SPORE includes three research projects; an administrative core; a biostatistics and bioinformatics core; a biospecimens, metabolomics, and pathology core; and developmental research and career enhancement programs. The three projects, chosen and refined with extensive input from our internal and external advisory boards, are designed to have significant potential to change clinical practice within five years. Project 1: HSPA Proteins in Advanced and Recurrent Endometrial Cancer Therapy. Project 2: Inhibiting AXL to Improve Treatment Response in Endometrial Cancer. Project 3: Improving Primary Prevention and Uterine Preservation in Premenopausal Women with Obesity and Endometrial Hyperplasia. Projects 1 and 2 are clinical/translational projects, whereas Project 3 is an early detection, prevention, or population science project. All three projects include clinical trials and represent carefully chosen marriages between selected endometrial cancer research priorities and the strengths of Washington University in St. Louis and our collaborators at the University of New Mexico and the University of Oklahoma Health Sciences Center. The overall aims of our SPORE are to 1) Test promising new therapies to treat or prevent endometrial cancer; 2) Elucidate the key biologic processes that drive endometrial cancer and develop novel biomarkers to predict development of endometrial cancer and response to therapies; 3) Leverage and enhance capacities of shared research resources; 4) Recruit and mentor new investigators and support innovative ideas in translational endometrial cancer research; 5) Facilitate collaboration of those interested in endometrial cancer research; and 6) Ensure equitable enrollment in clinical trials and involvement of diverse community members and investigators in research. In completing the work proposed here, we will test three new strategies to prevent or treat endometrial cancer. Future work can be directed at moving the most promising treatment approaches into larger trials. Additionally, we will obtain an unprecedented level of molecular, cellular, immunologic, and metabolomic detail regarding endometrial cancer and response to treatment, which will likely lead to development of additional novel clinical trials. Finally, by developing new ideas, investigators, and collaborations, we will expand the breadth and depth of research aimed at treating or preventing endometrial cancer.